These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21923736)

  • 101. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
    Paroni R; Comuzzi B; Arcelloni C; Brocco S; de Kreutzenberg S; Tiengo A; Ciucci A; Beck-Peccoz P; Genovese S
    Clin Chem; 2000 Nov; 46(11):1773-80. PubMed ID: 11067812
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A High-Throughput Assay for the Pancreatic Islet Beta-Cell Potassium Channel: Use in the Pharmacological Characterization of Insulin Secretagogues Identified from Phenotypic Screening.
    Song L; Barrett DG; Cox KL; Efanov AM; Syed SK; Tomandl D; Willard FS
    Assay Drug Dev Technol; 2021 Jan; 19(1):27-37. PubMed ID: 33164547
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs.
    Xu H; Murray M; McLachlan AJ
    Curr Drug Metab; 2009 Jul; 10(6):643-58. PubMed ID: 19799532
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
    Koltai MZ
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Sulfonylurea and the Heart: Theoretically a Compounded Question from a Pathophysiological Perspective.
    Farahani P
    J Popul Ther Clin Pharmacol; 2016 Sep; 23(3):e193-e195. PubMed ID: 27783474
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Use of hypoglycemic drugs during lactation.
    Glatstein MM; Djokanovic N; Garcia-Bournissen F; Finkelstein Y; Koren G
    Can Fam Physician; 2009 Apr; 55(4):371-3. PubMed ID: 19366943
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
    Sehra D; Sehra S
    Recent Adv Cardiovasc Drug Discov; 2015; 10(1):4-9. PubMed ID: 26767545
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.
    Ballagi-Pordány G; Köszeghy A; Koltai MZ; Aranyi Z; Pogátsa G
    Diabetes Res Clin Pract; 1990 Jan; 8(2):109-14. PubMed ID: 2106423
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanin e (A-4166)receptor in HIT T-15 cells. Displacement of [3H]glibenclamide.
    Fujita T; Seto Y; Kondo N; Kato R
    Biochem Pharmacol; 1996 Aug; 52(3):407-11. PubMed ID: 8687494
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.
    Riveline JP; Danchin N; Ledru F; Varroud-Vial M; Charpentier G
    Diabetes Metab; 2003 Jun; 29(3):207-22. PubMed ID: 12909809
    [TBL] [Abstract][Full Text] [Related]  

  • 111. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.
    Schwartz TB; Meinert CL
    Perspect Biol Med; 2004; 47(4):564-74. PubMed ID: 15467178
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study.
    Du J; Kleefstra N; Schrijnders D; Groenier KH; de Bock GH; Landman GWD
    Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1596-1605. PubMed ID: 32404443
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Total Synthesis of Glipizide and Glibenclamide in Continuous Flow.
    Sagandira CR; Khasipo AZ; Watts P
    Chemistry; 2021 Nov; 27(64):16028-16035. PubMed ID: 34633700
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Sulfonylureas induce cholesterol accumulation in cultured human intimal cells and macrophages.
    Sobenin IA; Maksumova MA; Slavina ES; Balabolkin MI; Orekhov AN
    Atherosclerosis; 1994 Feb; 105(2):159-63. PubMed ID: 8003091
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sulfonylurea derivatives and cancer, friend or foe?
    Hendriks AM; Schrijnders D; Kleefstra N; de Vries EGE; Bilo HJG; Jalving M; Landman GWD
    Eur J Pharmacol; 2019 Oct; 861():172598. PubMed ID: 31408647
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Structural Insights Into the High Selectivity of the Anti-Diabetic Drug Mitiglinide.
    Wang M; Wu JX; Chen L
    Front Pharmacol; 2022; 13():929684. PubMed ID: 35847046
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Comparison of hepatocellular carcinoma risk between patients treated with glimepiride and gliclazide.
    Lee JY; Kim G; Lee YH; Lee BW; Cha BS; Nam CM; Kang ES
    Diabetes Metab; 2019 Jan; 45(1):83-85. PubMed ID: 28778564
    [No Abstract]   [Full Text] [Related]  

  • 118. Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications.
    Digiacomo M; Martelli A; Testai L; Lapucci A; Breschi MC; Calderone V; Rapposelli S
    Bioorg Med Chem; 2015 Feb; 23(3):422-8. PubMed ID: 25577707
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Adverse effect on diabetes control of concomitant glibenclamide and tolbutamide.
    Katsumata K; Katsumata Y
    Lancet; 1991 Mar; 337(8741):614. PubMed ID: 1671966
    [No Abstract]   [Full Text] [Related]  

  • 120. Response to letter by Wang et al.: Comparing cardioprotection by remote ischaemic preconditioning in patients with and without diabetics.
    Kottenberg E; Peters J
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):769. PubMed ID: 24850086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.